درباره این اپیزود
In rare disease, time isn't money—it's lives.
In this episode of Med Tech Gurus, we sit down with Dr. Rob Freishtat, physician-scientist, former President and Co-Founder of Uncommon Cures, and board member of the Foundation for mRNA Medicines, to explore how clinical trial design is being rewritten for rare and ultra-rare conditions.
Traditional randomized, placebo-controlled trials—largely unchanged for decades—are often too rigid, too slow, and too burdensome for patients facing life-threatening conditions. Dr. Freishtat shares why adaptive trial designs, natural history cohorts, and patient-centric approaches are becoming essential to accelerating drug development.
We dive into the rise of N-of-1 therapies, mRNA-based treatments, and collaborative models that bring together regulators, academic centers, and industry in ways that were previously unthinkable. From the groundbreaking "Baby KJ" case to emerging ARPA-H initiatives, this conversation highlights a fundamental shift toward truly personalized medicine.
Dr. Freishtat also offers practical insights for founders navigating today's capital environment—why smaller, more efficient trials can unlock new funding pathways, and how aligning with mission-driven investors can accelerate both impact and execution.
If you're interested in rare disease innovation, clinical trial design, mRNA therapies, personalized medicine, or biotech startup strategy, this episode delivers a powerful look at how urgency is reshaping the future of healthcare.
